Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan

March 18, 2021
Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, is launching a PIII clinical trial of its plant-derived COVID-19 vaccine, combined with GlaxoSmithKline’s pandemic adjuvant, in the US and Canada. Mitsubishi Tanabe remained silent on its development plan in Japan. Medicago...read more